
Joelle Barrick learned in October 2021 that she carried a variant in the BRCA2 gene, but doctors at the time could not tell her whether it actually raised her cancer risk. It was labeled a variant of uncertain significance — essentially a genetic question mark. Four years later, a single phone call would upend everything she thought she knew about that result.
According to KFOX, Barrick continued routine screenings, including regular mammograms, for four years after her initial test, and nothing raised concerns. Her decision to get tested in the first place traced back to her mother, Lois Boll, who was diagnosed with pancreatic cancer and learned in 2019 that it was inoperable. Boll died at age 68 on Easter morning during the COVID-19 pandemic, after Barrick recalled being told that chemotherapy was not working and treatment would stop. Barrick has said her mother's illness led her to get tested and act proactively, and she underwent genetic testing after her mother's death.
A Reclassification Changes the Picture
About four years after that first test, Barrick's genetic testing company issued an updated report. The variant once considered uncertain was now classified as likely pathogenic, meaning updated scientific evidence suggested it was associated with disease. BRCA2 mutations are associated with increased breast cancer risk, and her doctor contacted her about the new result, setting in motion a chain of events Barrick says may have saved her life.
The estimates she was given about her personal risk vary depending on the account. In one description, her doctor told her the reclassified variant carried an 80% chance of developing breast cancer, the station's report states. In another account from the same outlet, Barrick recalled three separate doctors each telling her she faced a 70% chance, with all three recommending she get rid of the risk by having a double mastectomy. Three doctors ultimately recommended she undergo the preventive surgery.
Surgery Reveals What Screenings Missed
Barrick had no known cancer diagnosis before going into the operating room. She has said she questioned her decision right up until the IV went in, with her husband Jason — a retired firefighter and EMT — by her side helping care for her afterward. Six days after the operation, her doctor called again, this time to deliver news no one had expected: the surgery had revealed cancer in both breasts.
Barrick said she and Jason cried together after learning what the pathology had found. She has said her surgeon believed that waiting could have allowed the cancer to progress to stage one or stage two, potentially requiring chemotherapy and radiation — though that outcome was described as a possibility rather than a certainty. Barrick credits her mother's illness with prompting the genetic testing that eventually led her here, and she hopes sharing her experience will encourage others to take an active role in understanding their own health and medical history.
Why Old Genetic Results Don't Stay Static
Barrick's case touches on a broader pattern in genetic medicine: variants once classified as uncertain can be reclassified as scientists gather new evidence, and those reclassifications may ultimately be considered disease-increasing or benign. Millions of Americans have undergone genetic testing to assess disease risks, and genetic test results can change years after the original test was run.
KFOX reports that serious risks are found in roughly 10% of gene reclassification cases, and the outlet estimates that 53 million to 58 million Americans now have medical-grade genetic data sitting in hospital and lab databases. The station also notes that in 2025, a landmark study newly classified nearly 800 gene variants as cancer-causing, and that more than one in six women who had previously tested negative for certain mutations actually carried a dangerous variant when they were retested an average of five years later. Separately, a study on clinical decision-making published via PMC found reclassification in 21 of 97 patients with BRCA VUS; 95% of the reclassifications were benign and 5% deleterious.
Barrick's story is a reminder that an inconclusive genetic result isn't necessarily a closed chapter. For her, a report that sat unresolved for four years ended with a phone call, a surgery she almost talked herself out of, and a diagnosis no mammogram had caught.









